product discontinuation — e.g. “A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.” (United States)
Recent shortage history
Italy: resolved 29 Sept 2026 (began 29 Sept 2026)
Italy: resolved 21 Sept 2026 (began 21 Sept 2026)
Italy: resolved 10 Sept 2026 (began 10 Sept 2026)
Frequently asked questions
Is Mirikizumab-Mrkz currently in shortage?
Yes. As of the latest regulator updates, Mirikizumab-Mrkz has 2 active shortage notices across 1 country (United States). Status is refreshed daily from official regulatory sources.
Why is Mirikizumab-Mrkz in shortage?
Regulators attribute the current Mirikizumab-Mrkz shortages to product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Mirikizumab-Mrkz shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Get alerted when Mirikizumab-Mrkz status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Data on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.